文献速递银屑病与炎症性皮肤病

古塞奇尤单抗治疗银屑病患者1年后的真实世界证据:来自德国多中心非干预性前瞻性PERSIST研究

Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2022-05-25

PERSIST是一项德国多中心、前瞻性、非干预性研究,纳入303例中重度银屑病患者,评估古塞奇尤单抗治疗52周的疗效与安全性。结果显示平均PASI从基线16.4降至第28周3.0、第52周2.4,DLQI从13.7降至2.8和2.4,药物生存累积概率第52周为92.4%,未观察到新的安全信号。

要点

  • 古塞奇尤单抗治疗52周,平均PASI从基线16.4降至第28周3.0、第52周2.4。
  • 第52周58.4%患者达到绝对PASI≤1,64.6%患者达到DLQI≤1。
  • 药物生存累积概率第52周为92.4%,未观察到新的安全信号。

核心结论

  • 古塞奇尤单抗有效且耐受性良好,无论既往生物制剂治疗史、合并症或难治部位银屑病表现如何。
  • 未观察到新的安全信号。

研究设计与样本

  • PERSIST为前瞻性、非干预性、长期、德国多中心研究,纳入中重度银屑病患者。
  • 患者≥18岁,按常规临床实践处方古塞奇尤单抗,共303例患者入组并接受治疗。
  • 评估终点包括PASI、PGA、目标NAPSI和DLQI,随访至第52周。

主要发现

  • 平均PASI从基线16.4降至第28周3.0,第52周进一步降至2.4。
  • 绝对PASI≤1的患者比例从基线1.3%升至第28周50.8%,第52周58.4%。
  • PASI90和PASI100应答在第28周至第52周间也显示明显改善,与既往生物制剂治疗史无关。
  • 平均DLQI从基线13.7降至第28周2.8,第52周进一步降至2.4;第52周64.6%患者达到DLQI≤1。
  • 药物生存累积概率第52周为92.4%。

关键数值与推荐

  • 平均病程21.0年,77.2%患者既往接受过≥1种传统系统性治疗,51.2%患者既往接受过≥1种生物制剂治疗。
  • 难治部位银屑病皮损清除情况:PGA≤1的患者比例在第28周至第52周间增加。
  • 未观察到新的安全信号。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: PERSIST was a prospective, non-interventional, long-term, German multicentre study of patients with moderate-to-severe psoriasis receiving guselkumab, an approved monoclonal antibody that binds to the p19 subunit of interleukin (IL)-23, in a real-world setting. OBJECTIVES: Evaluation of the efficacy and safety of guselkumab, and its effect on health-related quality of life (HRQoL), in patients with moderate-to-severe psoriasis who have received 52 weeks of treatment. METHODS: Patients (≥18 years old) were prescribed guselkumab as per routine clinical practice. End points assessed include Psoriasis Area and Severity Index (PASI), Physician's Global Assessment (PGA), target Nail Psoriasis Severity Index (NAPSI), and the Dermatology Life Quality Index (DLQI). RESULTS: Overall, 303 patients were enrolled and treated with guselkumab. Mean disease duration was 21.0 years, and 77.2% and 51.2% of patients had received ≥1 prior conventional systemic or ≥1 prior biologic therapy, respectively. Mean PASI score decreased from 16.4 at baseline to 3.0 by Week (W) 28, and further decreased to 2.4 by W52, while the proportion of patients achieving an absolute PASI score of ≤1 increased from 1.3% at baseline, to 50.8% at W28 and to 58.4% by W52. PASI90 and PASI100 responses also showed marked improvements between W28 and W52, regardless of biologic treatment history. Clearance of psoriatic skin was observed in difficult-to-treat areas, with the percentage of patients achieving a PGA score ≤1 increasing between W28 and W52. Guselkumab improved HRQoL; mean DLQI score decreased from 13.7 at baseline to 2.8 by W28, and further decreased to 2.4 by W52. At W52, 64.6% of patients achieved a DLQI score ≤1. The cumulative probability of drug survival was 92.4% at W52. CONCLUSIONS: Guselkumab is efficacious and well tolerated regardless of previous biologic therapies, comorbidities or psoriasis manifestation in difficult-to-treat areas. No new safety signals were observed.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. Gerdes S, Asadullah K, Hoffmann M, et al. Real-world evidence from the non-interventional, prospective, German multicentre PERSIST study of patients with psoriasis after 1 year of treatment with guselkumab. J Eur Acad Dermatol Venereol. 2022. PMID: 35569014. doi:10.1111/jdv.18218

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。